RET and neoplasm: Several biomarkers not included in the survey are also important to test for in mBC, including RET fusions [51], NTRK fusions in the case of secretory carcinomas [52], as well as high tumor mutational burden (TMB) and high microsatellite instability (MSI) if the use of pembrolizumab is being considered [53,54].